Phase 2 Rare Disease Trial, Not Yet Recruiting NCT06804655 Sponsor: University of Zurich Condition: Rare Disease
Back to Rare Disease

Phase 2 Rare Disease Trial, Not Yet Recruiting

NCT06804655
Not Yet Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are 18 years of age or older (male or female)
  • You have been diagnosed with a specific type of brain or spinal tumor — such as glioblastoma that has stopped responding to treatment, a certain type of astrocytoma or oligodendroglioma, or other rare primary brain tumors — confirmed by a tissue sample analyzed according to current medical standards
  • Your overall health and ability to carry out daily activities meets a certain minimum level, as measured by a standard medical scoring tool (confirm with trial site)
  • Your doctor expects you to live for more than 12 weeks
  • Your doctor has determined that you have limited other treatment options available, regardless of how many treatments you have already tried
  • Surgery is medically recommended for you, and a tissue sample confirming a recurring brain tumor will be needed before any treatment in the trial begins
  • Your blood, kidney, and liver function are at acceptable levels
  • You are able to understand what the study involves, sign a consent form, and agree to follow the study's rules and attend required appointments

Who may not be able to join:

  • You are unable to have an MRI scan of the brain or spine
  • You are currently receiving other drug treatments aimed at treating your tumor
  • You are planning to receive radiation therapy
  • You are currently taking part in another experimental anti-tumor treatment study
  • Your doctor feels you are unlikely to follow the study's procedures and requirements
  • You are pregnant, or you intend to become pregnant during the study; women who could potentially become pregnant must have a negative pregnancy test before joining
  • You are currently breastfeeding and are not willing to stop nursing before the first treatment and for the period specified in the study guidelines
  • You are sexually active and able to have children, but are not willing to use an effective form of contraception throughout the study

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: +41442555500

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Not Yet Recruiting
Phase
Phase 2
Registry
ClinicalTrials.gov
Start date
1 June 2026
Est. completion
15 September 2028

Where this trial is recruiting

🇨🇭 Switzerland

Primary endpoints

To demonstrate the overall feasibility of pharmacoscopy-guided treatment for patients with refractory primary brain tumors

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov